Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / AVXL - Neutral On Anavex: Evaluating The Potential In Neurodegenerative Diseases

AVXL - Neutral On Anavex: Evaluating The Potential In Neurodegenerative Diseases

Anavex Life Sciences Corp.

2024-05-22 16:11:06 ET

Summary

  • Anavex Life Sciences is a clinical-stage biopharmaceutical company developing innovative treatments for neurodegenerative diseases.
  • Its leading drug candidate, Anavex 2-73 (Blarcamesine), targets the Sigma-1 and muscarinic receptors in the brain to enhance neuroprotection and cognitive function.
  • Anavex's current valuation includes a premium over peers, and the company has a three-year cash runway based on its current cash burn rate.
  • While Blarcamesine shows statistically significant results, its modest efficacy may lead to a limited market impact, leading to a "hold" rating for AVXL.

...

For further details see:

Neutral On Anavex: Evaluating The Potential In Neurodegenerative Diseases
Stock Information
Company Name: Anavex Life Sciences Corp.
Stock Symbol: AVXL
Market: NASDAQ
Website: anavex.com
Menu
AVXL AVXL Quote AVXL Short AVXL News AVXL Articles AVXL Message Board
Get AVXL Alerts

News, Short Squeeze, Breakout and More Instantly...